BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/27/2025 7:53:56 AM | Browse: 122 | Download: 678
 |
Received |
|
2025-07-25 01:22 |
|
Peer-Review Started |
|
2025-07-25 01:22 |
|
First Decision by Editorial Office Director |
|
2025-08-15 09:05 |
|
Return for Revision |
|
2025-08-15 09:05 |
|
Revised |
|
2025-08-28 14:26 |
|
Publication Fee Transferred |
|
2025-08-29 03:32 |
|
Second Decision by Editor |
|
2025-10-22 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-10-22 08:21 |
|
Articles in Press |
|
2025-10-22 08:21 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-11-18 00:37 |
|
Publish the Manuscript Online |
|
2025-11-27 07:53 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Li-Jun Wang, Yong Cui, Long-Fei Huang, Jing-Qing Zhang, Ting-Ting Zhao, Hong-Wei Wang, Ming Liu, Ke-Min Jin, Kun Wang and Bao-Cai Xing |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Special Fund for Clinical Research of Wu Jieping Medical Foundation |
320.6750.19088-38 |
| Clinical Research Fund for Distinguished Young Scholars of Beijing Cancer Hospital |
LGH2019101, LGH2022005 |
|
| Corresponding Author |
Bao-Cai Xing, MD, Department of Hepatopancreatobiliary Surgery Unit I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. xingbaocai88@sina.com |
| Key Words |
Hepatocellular carcinoma; Molecular biomarkers; Sintilimab; Lenvatinib; RNA sequencing; Whole-exome sequencing |
| Core Tip |
The efficacy of sintilimab plus lenvatinib in hepatocellular carcinoma is highly variable. This study integrated RNA sequencing, immune profiling, and whole-exome sequencing to identify predictive biomarkers. High long intergenic non-protein coding RNA 01554 expression, elevated CD4+ central memory T cells, and solitary tumors were independent predictors of prolonged progression-free survival. These findings highlight the potential of molecular and immune markers to guide individualized treatment strategies in advanced hepatocellular carcinoma. |
| Publish Date |
2025-11-27 07:53 |
| Citation |
Wang LJ, Cui Y, Huang LF, Zhang JQ, Zhao TT, Wang HW, Liu M, Jin KM, Wang K, Xing BC. Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma. World J Hepatol 2025; 17(11): 112364
|
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i11/112364.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i11.112364 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
